Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

45.76 -1.40 (-2.97%)
Streaming Delayed Price Updated: 3:23 PM EST, Dec 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 315,755
Open 47.01
Bid (Size) 45.72 (100)
Ask (Size) 45.80 (400)
Prev. Close 47.16
Today's Range 45.76 - 47.24
52wk Range 29.16 - 57.65
Shares Outstanding 53,145,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Unprofitable Stocks We Find Risky
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
Via StockStory
News headline image
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+25.6%
+25.6%
1 Month
+0.8%
+0.8%
3 Month
-0.1%
-0.1%
6 Month
+37.5%
+37.5%
1 Year
+24.8%
+24.8%

More News

Read More
News headline image
1 Healthcare Stock Worth Your Attention and 2 Facing Headwinds
Via StockStory
Topics Stocks
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
A Preview Of Supernus Pharmaceuticals's Earnings ↗
Via Benzinga
News headline image
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗
Via The Motley Fool
News headline image
3 Russell 2000 Stocks Walking a Fine Line
Via StockStory
News headline image
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
5 Must-Read Analyst Questions From Supernus Pharmaceuticals’s Q3 Earnings Call
Via StockStory
Topics Earnings
News headline image
Why Supernus Pharmaceuticals (SUPN) Shares Are Trading Lower Today
Via StockStory
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
SUPN Q3 Deep Dive: Growth Drivers Offset By Supply Constraints and Integration Costs
Via StockStory
Topics Supply Chain
News headline image
Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Strong Q3
Via StockStory
News headline image
Supernus Announces Third Quarter 2025 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Spotting Winners: Royalty Pharma (NASDAQ:RPRX) And Branded Pharmaceuticals Stocks In Q2
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
Via Benzinga
News headline image
Supernus Pharmaceuticals (SUPN) Reports Q3: Everything You Need To Know Ahead Of Earnings
Via StockStory
Topics Artificial Intelligence
News headline image
3 Cash-Producing Stocks That Fall Short
Via StockStory
News headline image
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Emerges as a Top Affordable Growth Candidate ↗
Via Chartmill
News headline image
Deep Dive Into Supernus Pharmaceuticals Stock: Analyst Perspectives (5 Ratings) ↗
Via Benzinga
News headline image
3 Small-Cap Stocks We’re Skeptical Of
Via StockStory
News headline image
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Supernus Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Supernus Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Supernus Pharmaceuticals, Inc. - Common Stock trade on?
Supernus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock is SUPN on the Nasdaq Stock Market
What is the current price of Supernus Pharmaceuticals, Inc. - Common Stock?
The current price of Supernus Pharmaceuticals, Inc. - Common Stock is 45.76
When was Supernus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Supernus Pharmaceuticals, Inc. - Common Stock was at 12/09/25 03:23 PM ET
What is the market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock is 2.43B
How many shares of Supernus Pharmaceuticals, Inc. - Common Stock are outstanding?
Supernus Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.